295 reports of this reaction
8.7% of all TIOCONAZOLE reports
#3 most reported adverse reaction
VULVOVAGINAL SWELLING is the #3 most commonly reported adverse reaction for TIOCONAZOLE, manufactured by Insight Pharmaceuticals LLC. There are 295 FDA adverse event reports linking TIOCONAZOLE to VULVOVAGINAL SWELLING. This represents approximately 8.7% of all 3,387 adverse event reports for this drug.
Patients taking TIOCONAZOLE who experience vulvovaginal swelling should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
VULVOVAGINAL SWELLING is moderately reported among TIOCONAZOLE users, representing a notable but not dominant share of adverse events.
In addition to vulvovaginal swelling, the following adverse reactions have been reported for TIOCONAZOLE:
The following drugs have also been linked to vulvovaginal swelling in FDA adverse event reports:
VULVOVAGINAL SWELLING has been reported as an adverse event in 295 FDA reports for TIOCONAZOLE. This does not prove causation, but indicates an association observed in post-market surveillance data.
VULVOVAGINAL SWELLING accounts for approximately 8.7% of all adverse event reports for TIOCONAZOLE, making it one of the most commonly reported side effect.
If you experience vulvovaginal swelling while taking TIOCONAZOLE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.